Additional file 1 of EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

Additional file 1: Table S1. Detailed information of EPHA5 mutations in NSCLCs from MSKCC cohort.

补充材料1：表S1。纪念斯隆凯特琳癌症中心（Memorial Sloan Kettering Cancer Center, MSKCC）队列中非小细胞肺癌（Non-Small Cell Lung Cancers, NSCLCs）的EPHA5基因突变详细信息。